Bhageria Industries Q2 & H1 FY26 Earnings Call Transcript
Bhageria Industries' Q2 & H1 FY26 earnings call transcript highlights strong financial performance, capacity expansions, and new product launches, with a focus on specialty chemicals and renewable energy.
The announcement provides insights into the company's performance, expansion plans, and future strategies, which can have a moderate impact on investor sentiment and stock performance.
The conference call reflects positive financial results, capacity expansions, and strategic initiatives, indicating a positive outlook for the company.
* Bhageria Industries held its Q2 & H1 FY26 earnings conference call on October 28, 2025. * Total income for Q2 FY26 stood at ₹260.02 crore, a 55.6% year-on-year growth. * EBITDA increased 47% to ₹24.75 crore. * Net profit for the quarter rose 80% year-on-year to ₹11.47 crore. * Total income for the first half of FY26 was ₹369.99 crore, up 48% year-on-year. * EBITDA rose 48% to ₹48.94 crore, and net profit grew 83% to ₹22.36 crore. * Commercial production of Plasticizers started by the end of December 2025. * Expansion of H-ACID capacity from 400 MT/month to 500 MT/month at Tarapur with an investment of around ₹5 crore is scheduled for completion within the next 3 months. * The company expects additional annual revenue of ₹50 crore-₹75 crore from the H-ACID capacity expansion. * CARE Rating has reaffirmed Bhageria Industries' long-term and short-term facilities at a stable A1 for a total amount of ₹21 crore. * The company expects revenue between ₹725 crore and ₹775 crore from the chemical segment for the full year. * Management anticipates a 2%-3% margin improvement, potentially reaching 13%-14%. * Plasticizer plant capacity is planned at 2,000 tons per month. * The 32-megawatt solar project has a power purchase agreement (PPA) at ₹3.08, with expected revenue of ₹22 crore per annum and an equity IRR of approximately 16%. * H-ACID capacity expansion is expected to be online by January end. * The company is manufacturing Dexamethasone base and Dexamethasone Sodium Phosphate in the pharmaceutical segment and is planning to file US DMF in November and Japan DMF by December for Methylcobalamin. * The company expects to break even in the pharma segment in the next 2 years. * Management mentioned that current utilization is about 95%-97% of production.
What to do with a filing like this
Bhageria Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bhageria Industries Limited. Read the original for the full detail.